Small Cell Lung Cancer Therapeutics Market Value to Exceed of USD 12.9 Bn by 2031,…
<!-- Name:DistributionId Value:8832874 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
SCLC
FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC
SHANGHAI, China, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based…
‘Clinically Meaningful’ Improvement in SCLC Patients With…
VIENNA -- Long-term results from the phase III KEYNOTE-604 trial appeared to strengthen the case of pembrolizumab (Keytruda) combined…
Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research…
Las Vegas, USA, April 14, 2022 (GLOBE NEWSWIRE) -- Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Small-cell Lung…
Lurbinectedin-Doxorubicin Combo Misses Survival Mark in SCLC
A combination treatment for relapsed small-cell lung cancer (SCLC), involving the recently FDA-approved…
Atezo-Chemo Benefit in Extensive-Stage SCLC Seen Outside Trials, Too
At the virtual European Society for Medical Oncology (ESMO) meeting, researchers explored the clinical…
Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLC
Consolidation therapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) after chemoradiotherapy…
IMpower133: Real-World vs Clinical Trial Data in SCLC
At the virtual European Society for Medical Oncology (ESMO) meeting, researchers explored the clinical…